Fractyl Health, Inc. Overview
Pro stress-test →Fractyl Health is a metabolic therapeutics company developing novel procedural and gene therapies for type 2 diabetes and obesity treatment. The company's lead program, Revita, is an outpatient procedural therapy using duodenal mucosal resurfacing to address metabolic dysfunction caused by high-fat and high-sugar diets.
Strategic Profile
Pro stress-test →Fractyl is positioned at the intersection of GLP-1 resistance and next-generation metabolic disease therapy. With pivotal trial data expected in H2 2026 and an FDA De Novo submission pathway, the company is advancing from clinical to commercial-stage operations while maintaining significant institutional backing and a cash runway into early 2027.
Competitive Landscape
Pro stress-test →Fractyl competes in the expanding obesity/metabolic disease treatment space against procedural competitors (EndoBarrier, AspireAssist), pharmaceutical GLP-1 leaders (Novo Nordisk, Eli Lilly), and emerging metabolic therapy platforms. Revita's unique duodenal resurfacing approach targets GLP-1 resistance/maintenance, positioning it as complementary to rather than directly competing with GLP-1 agonists.
Industry Context
Fractyl Health, Inc. operates in Metabolic Therapeutics / Obesity and Type 2 Diabetes Treatment.
Key facts
Founded: 2010 · Headquarters: Burlington, Massachusetts · Market cap: $72M